New MSK research shows how BRCA2-mutant cancers rely on a previously unknown DNA repair lifeline; helps explain the effectiveness of cyclophosphamide, a drug used in bone marrow transplants; and finds small cell transformation persists despite early chemotherapy in high-risk EGFR-mutant lung cancer.